>the conundrum is that patients with DIC are at risk of both clotting and bleeding. The clotting results in a consumptive coagulopathy which then predisposes to hemorrhage<
rFVIIa is sometimes given when this happens, but that’s not a market I’d expect GTC to pursue, for obvious reasons
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”